Drug and medical device maker Abbott Laboratories said Friday it withdrew its request for U.S. and European approval of the potential psoriasis drug briakinumab.
The company said in a filing with the Securities and Exchange Commission it made the decision following feedback from regulatory authorities that potential additional studies might be necessary on the drug.
via businessweek.com
No comments:
Post a Comment